Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

被引：66
|
作者：
Demeter, LM
Shafer, RW
Meehan, PM
Holden-Wiltse, J
Fischl, MA
Freimuth, WW
Para, MF
Reichman, RC
机构：
[1] Univ Rochester, Infect Dis Unit, Sch Med & Dent, Rochester, NY 14642 USA
[2] Stanford Univ, Palo Alto, CA 94304 USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[4] Univ Miami, Miami, FL 33152 USA
[5] Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA
[6] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 03期
关键词：
D O I：
10.1128/AAC.44.3.794-797.2000
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.
引用
收藏
页码：794 / 797
页数：4
相关论文
共 50 条
  • [1] ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy
    Para, MF
    Meehan, P
    Holden-Wiltse, J
    Fischl, M
    Morse, G
    Shafer, R
    Demeter, LM
    Wood, K
    Nevin, T
    Virani-Ketter, N
    Freimuth, WW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1373 - 1378
  • [2] Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats
    Chang, M
    Sood, VK
    Wilson, GJ
    Kloosterman, DA
    Sanders, PE
    Hauer, MJ
    Fagerness, PE
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (02) : 228 - 242
  • [3] Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication
    Huang, W
    Gamarnik, A
    Limoli, K
    Petropoulos, CJ
    Whitcomb, JM
    JOURNAL OF VIROLOGY, 2003, 77 (02) : 1512 - 1523
  • [4] Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
    Davey, RT
    Chaitt, DG
    Reed, GF
    Freimuth, WW
    Herpin, BR
    Metcalf, JA
    Eastman, PS
    Falloon, J
    Kovacs, JA
    Polis, MA
    Walker, RE
    Masur, H
    Boyle, J
    Coleman, S
    Cox, SR
    Wathen, L
    Daenzer, CL
    Lane, HC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) : 1657 - 1664
  • [5] Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
    Young, B
    Johnson, S
    Bahktiari, M
    Shugarts, D
    Young, RK
    Allen, M
    Ramey, RR
    Kuritzkes, DR
    JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (05): : 1497 - 1501
  • [6] Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase
    Tachedjian, G
    French, M
    Mills, J
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 3038 - 3043
  • [7] Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations
    Basavapathruni, Aravind
    Vingerhoets, Johan
    de Bethune, Marie-Pierre
    Chung, Raymond
    Bailey, Christopher M.
    Kim, Jiae
    Anderson, Karen S.
    BIOCHEMISTRY, 2006, 45 (23) : 7334 - 7340
  • [8] Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer
    Wapling, J
    Moore, KL
    Sonza, S
    Mak, J
    Tachedjian, G
    JOURNAL OF VIROLOGY, 2005, 79 (16) : 10247 - 10257
  • [9] Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial
    Joly, V
    Moroni, M
    Concia, E
    Lazzarin, A
    Hirschel, B
    Jost, J
    Chiodo, F
    Bentwich, Z
    Love, WC
    Hawkins, DA
    Wilkins, EGL
    Gatell, AJ
    Vetter, N
    Greenwald, C
    Freimuth, WW
    De Cian, W
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) : 3155 - 3157
  • [10] Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase
    Smith, Robert A.
    Anderson, Donovan J.
    Preston, Bradley D.
    JOURNAL OF VIROLOGY, 2006, 80 (14) : 7169 - 7178
12345